Radiotherapy/Radiation / selectivity Cancer Research Results

Rad, Radiotherapy/Radiation: Click to Expand ⟱
Features:
Treatment of disease with radiation, especially by selective irradiation with x-rays or other ionizing radiation and by ingestion of radioisotopes.

Radiosensitizer
Atorvaqone, (mitochondria inhibitor) decrease O2 consumption making more O2 available as a radiosensitizer.
-Hypoxia (low oxygen levels) within tumors is a major cause of resistance to radiotherapy


selectivity, selectivity: Click to Expand ⟱
Source:
Type:
The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues.

Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance

Factors that affect selectivity:
1. Ability of Cancer cells to preferentially absorb a product/drug
-EPR-enhanced permeability and retention of cancer cells
-nanoparticle formations/carriers may target cancer cells over normal cells
-Liposomal formations. Also negatively/positively charged affects absorbtion

2. Product/drug effect may be different for normal vs cancer cells
- hypoxia
- transition metal content levels (iron/copper) change probability of fenton reaction.
- pH levels
- antiOxidant levels and defense levels

3. Bio-availability
Scientific Papers found: Click to Expand⟱
4400- AgNPs,  Rad,    Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells
- in-vitro, BC, MCF7 - in-vitro, Nor, MCF10 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vivo, BC, MDA-MB-231
ROS↑, DNAdam↑, selectivity↑, TumCG↓, RadioS↑, Dose↝, selectivity↑, other↝, eff↓, eff↑, γH2AX↑, Dose↓, eff↑,
3163- Ash,  Rad,    Withaferin A, a steroidal lactone, selectively protects normal lymphocytes against ionizing radiation induced apoptosis and genotoxicity via activation of ERK/Nrf-2/HO-1 axis
*radioP↑, selectivity↑, *Casp3↓, *DNAdam↓, *ROS↓, *GSH↓, *NRF2↑, *HO-1↑, *Catalase↑, *SOD↑, *Prx↑, *ERK↑,
4822- ASTX,  Rad,    Astaxanthin Synergizes with Ionizing Radiation (IR) in Oral Squamous Cell Carcinoma (OSCC)
tumCV↓, selectivity↑, RadioS↑, GPx4↓, Ferroptosis↑,
2022- BBR,  GoldNP,  Rad,    Berberine-loaded Janus gold mesoporous silica nanocarriers for chemo/radio/photothermal therapy of liver cancer and radiation-induced injury inhibition
- in-vitro, Liver, SMMC-7721 cell - in-vitro, Nor, HL7702
*toxicity↓, radioP↑, BioAv↑, AntiTum↑, selectivity↑, eff↑, chemoP↑,
5587- BetA,  Rad,    Effects of betulinic acid alone and in combination with irradiation in human melanoma cells
- in-vitro, Melanoma, NA
TumCG↓, RadioS↑, Apoptosis↑, selectivity↑,
1979- CUR,  Rad,    Dimethoxycurcumin, a metabolically stable analogue of curcumin enhances the radiosensitivity of cancer cells: Possible involvement of ROS and thioredoxin reductase
- in-vitro, Lung, A549
eff↑, ROS↑, GSH/GSSG↓, TrxR↓, selectivity↑,
1980- CUR,  Rad,    Thioredoxin reductase-1 (TxnRd1) mediates curcumin-induced radiosensitization of squamous carcinoma cells
- in-vitro, Cerv, HeLa - in-vitro, Laryn, FaDu
selectivity↑, RadioS↑, TrxR↓, ROS↑, ERK↑, Dose∅, cl‑PARP↑,
5195- DCA,  Rad,    Dichloroacetate Radiosensitizes Hypoxic Breast Cancer Cells
- in-vitro, BC, 4T1 - in-vitro, BC, EMT6
PDKs↑, ROS↑, p‑PDH↓, ECAR↓, lactateProd↓, selectivity↓, RadioS↑,
7100- Geld,  Rad,    Preferential sensitization of tumor cells to radiation by heat shock protein 90 inhibitor geldanamycin
- in-vitro, Var, NA
HSP90↓, Akt↓, RadioS↑, selectivity↑,
1987- PTL,  Rad,    A NADPH oxidase dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Nor, PrEC
selectivity↑, RadioS↑, ROS↑, *ROS∅, NADPH↑, Trx↓, PI3K↑, Akt↑, p‑FOXO3↓, SOD2↓, Catalase↓, radioP↑, *NADPH∅, *GSH↑, *GSH/GSSG↑, *NRF2↑,
5038- SAS,  Rad,    Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma
- in-vivo, Melanoma, B16-F10
xCT↓, ROS↑, RadioS↓, GSH↓, selectivity↑, DNArepair↓, TumCCA↑, H2O2↑, Dose↝,
4615- Se,  Rad,    Selenium as an adjuvant for modification of radiation response
- Review, Nor, NA
*antiOx↑, *radioP↑, *GSH↑, *GPx↑, *Dose↝, selectivity↑, RadioS↑,
5078- SSE,  Rad,    Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer
- Trial, Pca, NA
Half-Life↝, OS↑, Pain↓, PSA↓, GSH↓, ROS↑, selectivity↑, TumCG↓, AR↓, Dose↑, ChemoSen↑, RadioS↑,
6894- VitC,  Rad,    Pharmacological Ascorbate as a Means of Sensitizing Cancer Cells to Radio-Chemotherapy While Protecting Normal Tissue
- Review, Var, NA
AntiTum↑, selectivity↑, H2O2↑, RadioS↑, radioP↑, ChemoSen↑, ROS↑, DNAdam↑,

Showing Research Papers: 1 to 14 of 14

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 14

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   Ferroptosis↑, 1,   GPx4↓, 1,   GSH↓, 2,   GSH/GSSG↓, 1,   H2O2↑, 2,   ROS↑, 8,   SOD2↓, 1,   Trx↓, 1,   TrxR↓, 2,   xCT↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ECAR↓, 1,   lactateProd↓, 1,   NADPH↑, 1,   p‑PDH↓, 1,   PDKs↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Akt↑, 1,   Apoptosis↑, 1,   Ferroptosis↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,   tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP90↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 2,   DNArepair↓, 1,   cl‑PARP↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↑, 1,   p‑FOXO3↓, 1,   PI3K↑, 1,   TumCG↓, 3,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

PSA↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   ChemoSen↑, 2,   Dose↓, 1,   Dose↑, 1,   Dose↝, 2,   Dose∅, 1,   eff↓, 1,   eff↑, 4,   Half-Life↝, 1,   RadioS↓, 1,   RadioS↑, 10,   selectivity↓, 1,   selectivity↑, 14,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 2,   chemoP↑, 1,   OS↑, 1,   Pain↓, 1,   radioP↑, 3,  
Total Targets: 54

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   GSH↓, 1,   GSH↑, 2,   GSH/GSSG↑, 1,   HO-1↑, 1,   NRF2↑, 2,   Prx↑, 1,   ROS↓, 1,   ROS∅, 1,   SOD↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

NADPH∅, 1,  

Cell Death(tgid=5) ⓘ

Casp3↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,  

Functional Outcomes(tgid=23) ⓘ

radioP↑, 2,   toxicity↓, 1,  
Total Targets: 19

Scientific Paper Hit Count for: selectivity, selectivity
14 Radiotherapy/Radiation
2 Curcumin
1 Silver-NanoParticles
1 Ashwagandha(Withaferin A)
1 Astaxanthin
1 Berberine
1 Gold NanoParticles
1 Betulinic acid
1 Dichloroacetate
1 Geldanamycin
1 Parthenolide
1 Sulfasalazine
1 Selenium
1 Selenite (Sodium)
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:201  Target#:1110  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page